Fortis Healthcare Limited — PPTs, 20-05-2025: Investor Presentation

1. Financial Highlights:

Consolidated revenue grew 12.4% QoQ to ₹2,007 Cr and 12.9% YoY to ₹7,783 Cr for FY25. Operating EBITDA rose 14.3% QoQ to ₹435 Cr and 25.3% YoY to ₹1,588 Cr, with margins improving to 21.7% (Q4) and 20.4% (FY25). Hospital revenues increased 14.2% QoQ to ₹1,701 Cr and 14.8% YoY to ₹6,528 Cr, with EBITDA margins around 22% in Q4 and 20.5% for FY25. Diagnostics showed moderate growth: 3.5% QoQ to ₹306 Cr and 4% YoY to ₹1,255 Cr, and margins expanded to ~20%. Net debt rose to ₹1,694 Cr (Net Debt/EBITDA 0.93x), largely due to Agilus Diagnostics acquisition.

2. Strategic Initiatives & Growth Drivers:

ARPOB increased 8-9% with occupancy rising to 69% from 65%, fueling revenue growth. Digital revenue surged 35.1% for FY25, now ~30% of hospital income. Expansion continues with operational ramp-up at Manesar (350 beds), FMRI Noida, and upcoming towers at Faridabad and FMRI, targeting ~2,000 new beds from FY26-29. Acquisition of Shrimann Superspecialty Hospital (228 beds) enhances Punjab presence, aiming for 450+ beds.

3. Business Developments:

Acquired ‘Fortis’ brand rights for ₹200 Cr, strengthening brand control. Increased stake in Agilus Diagnostics to 89.2%, boosting diagnostic integration. Divested Bengaluru’s Richmond Road facility as part of portfolio optimization.

4. Market Position & Competitive Advantage:

Fortis holds leadership with ~4,750 beds across 27 facilities and 404 diagnostic labs. Specialty verticals—oncology, neurosciences, cardiac, gastroenterology, orthopedics, renal—grew 16% YoY, contributing 62% of hospital revenue. Strong clinical innovations include a 72% rise in robotic surgeries.

5. Investor Implications:

Revenue and margin growth driven by occupancy, ARPOB, and digital channels signal positive growth potential. Acquisitions and bed expansion support scalability but elevated net debt warrants attention. Dividend of ₹1/share indicates confidence in cash flow.

Fortis shows robust operational momentum, brand consolidation, and balanced growth in hospital and diagnostics, offering encouraging prospects with manageable leverage.